http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 17:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Decoy+Therapeutics+Inc.++++++++++++++/26785084.html si-local-file:///var/storage/secattach/20260717/26785084.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Decoy+Therapeutics+Inc.++++++++++++++/26785084.html Fri, 17 Jul 2026 17:08:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Decoy+Therapeutics+Inc.++++++++++++++/26785084.html si-local-file:///var/storage/secattach/20260717/26785084.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Decoy+Therapeutics+Inc.++++++++++++++/26785084.html Fri, 17 Jul 2026 17:08:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Decoy+Therapeutics+Inc.+++For%3A+Jul+14/26774948.html si-local-file:///var/storage/secattach/20260715/26774948.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Decoy+Therapeutics+Inc.+++For%3A+Jul+14/26774948.html Wed, 15 Jul 2026 17:14:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Decoy+Therapeutics+Inc.+++For%3A+Jul+14/26774948.html si-local-file:///var/storage/secattach/20260715/26774948.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Decoy+Therapeutics+Inc.+++For%3A+Jul+14/26774948.html Wed, 15 Jul 2026 17:14:00 -0400 DCOY O.22255725 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html <p>Decoy Therapeutics Inc. (Nasdaq: DCOY) announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the company's 2026 Annual Meeting of Stockholders, held July 14, 2026.</p> <p>Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.</p> <p>Gauthier has served as Senior Vice President and Regional Head for Australia, Canada, and the United Kingdom at Moderna since 2025, overseeing strategy and operations across biomanufacturing, national health security partnerships, and commercialization. She previously served as General Manager of Moderna Canada, where she helped oversee delivery of more than 50 million COVID-19 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html Wed, 15 Jul 2026 09:25:39 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html <p>Decoy Therapeutics Inc. (Nasdaq: DCOY) announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the company's 2026 Annual Meeting of Stockholders, held July 14, 2026.</p> <p>Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.</p> <p>Gauthier has served as Senior Vice President and Regional Head for Australia, Canada, and the United Kingdom at Moderna since 2025, overseeing strategy and operations across biomanufacturing, national health security partnerships, and commercialization. She previously served as General Manager of Moderna Canada, where she helped oversee delivery of more than 50 million COVID-19 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html Wed, 15 Jul 2026 09:25:39 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html <p>Decoy Therapeutics Inc. (Nasdaq: DCOY) announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the company's 2026 Annual Meeting of Stockholders, held July 14, 2026.</p> <p>Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.</p> <p>Gauthier has served as Senior Vice President and Regional Head for Australia, Canada, and the United Kingdom at Moderna since 2025, overseeing strategy and operations across biomanufacturing, national health security partnerships, and commercialization. She previously served as General Manager of Moderna Canada, where she helped oversee delivery of more than 50 million COVID-19 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html Wed, 15 Jul 2026 09:25:39 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html <p>Decoy Therapeutics Inc. (Nasdaq: DCOY) announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the company's 2026 Annual Meeting of Stockholders, held July 14, 2026.</p> <p>Gauthier joins Class II directors Rick Pierce and Jon Lieber, both of whom were re-elected at the same meeting.</p> <p>Gauthier has served as Senior Vice President and Regional Head for Australia, Canada, and the United Kingdom at Moderna since 2025, overseeing strategy and operations across biomanufacturing, national health security partnerships, and commercialization. She previously served as General Manager of Moderna Canada, where she helped oversee delivery of more than 50 million COVID-19 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+elects+Moderna+executive+to+its+board/26772069.html Wed, 15 Jul 2026 09:25:39 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:DCOY" idsrc="xmltag.org" >Decoy Therapeutics Inc.</span> (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected <person>Patricia Gauthier</person>, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held <chron>July 14, 2026</chron> Ms. Gauther will serve with the Company's other two Class II directors, <person>Rick Pierce</person> and <person>Jon Lieber</person>, each of whom were re-elected at the annual meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics+Stockholders+Elect+Patricia+Gauthier+to+Board+of+Directors/26772067.html Wed, 15 Jul 2026 09:24:00 -0400 A.26182308 DCOY O.03301479 O.22255725 http://www.streetinsider.com/Equity+Offerings/Decoy+Therapeutics+%28DCOY%29+files+for+3.77M+share+offering+by+selling+stockholders/26757624.html <p>Decoy Therapeutics (NASDAQ: DCOY) has filed for up to 3,766,500 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Decoy+Therapeutics+%28DCOY%29+files+for+3.77M+share+offering+by+selling+stockholders/26757624.html Fri, 10 Jul 2026 16:28:40 -0400 DCOY http://www.streetinsider.com/Corporate+News/Decoy+Therapeutics+%28DCOY%29+files+for+3.77M+share+offering+by+selling+stockholders/26757624.html <p>Decoy Therapeutics (NASDAQ: DCOY) has filed for up to 3,766,500 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Decoy+Therapeutics+%28DCOY%29+files+for+3.77M+share+offering+by+selling+stockholders/26757624.html Fri, 10 Jul 2026 16:28:40 -0400 DCOY http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26757604.html si-local-file:///var/storage/secattach/20260710/26757604.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26757604.html Fri, 10 Jul 2026 16:26:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26757604.html si-local-file:///var/storage/secattach/20260710/26757604.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26757604.html Fri, 10 Jul 2026 16:26:00 -0400 DCOY O.22255725 http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN